Latest News for: tce

Edit

Ripon taking steps to get Well 3 back online with TCE treatment plan

Manteca Bulletin 10 Oct 2026
Steps could be taken Tuesday by the Ripon City Council that could ultimately allow Well 3 to produce safe drinking water ....
Edit

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation ...

Watauga Democrat 03 Oct 2026
SHANGHAI and HONG KONG, Oct.
Edit

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

PR Newswire 03 Oct 2026
... ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform.
Edit

How merging Tata Electronics, TCE could help Tata Sons avoid an RBI-mandated listing

Indian Express 29 Sep 2026
.
Edit

Tata Trusts Propose TESS, TCE Merger Into Tata Sons To Shed CIC Tag, Avoid Listing

News18 29 Sep 2026
The proposed restructuring is aimed at ensuring that the reorganised entity will neither qualify as a Non-Banking Financial Company (NBFC) nor a Core Investment Company (CIC) ....
Edit

Tata Trusts picks TCE, TESS to enhance revenue, side-step NBFC classification

Live Mint 29 Sep 2026
Tata Trusts plans to merge Tata Consulting Eng Electronics into Tata Sons, enhancing its reven potentially sidestepping non-banking financia classification. The move also simplifies owners promoting easier regulatory navigation ....
Edit

BREAKING: Tata Trusts Propose TESS, TCE Merger Into Tata Sons To Shed CIC Tag, Avoid Listing

News18 29 Sep 2026
Tata Trusts, which hold a 66% stake in Tata Sons Private Limited (TSPL), have proposed a strategic reorganisation of the ...
Edit

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences (GSK plc)

Public Technologies 15 Sep 2026
GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held biotechnology company.
Edit

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences (Lilly Asia Ventures)

Public Technologies 15 Sep 2026
GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held biotechnology company.
Edit

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences (Form 6-K) (GSK plc)

Public Technologies 15 Sep 2026
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences ... Trispecific TCE targeting T cells and two tumour antigens has potential for differentiated efficacy and safety over current TCEs.
Edit

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC�-TCE Program

Nasdaq Globe Newswire 02 Jul 2026
VERAXA Biotech announces further progress with lead BiTAC� T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM ... .
Edit

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program

The Daily Record - Dunn 02 Jul 2026
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to ....
  • 1

Article Search

tools
×
×
×
×